Aurobindo Pharma was founded in 1986. The company commenced its operations in 1988–89 with a single unit that manufactured semi-synthetic penicillin (SSP) at Pondicherry. The company became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995.
In addition to being the market leader in SSPs, Aurobindo Pharma has presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others.
The company has nine units for APIs/intermediates and seven units for formulations, which are designed to meet the requirements of both advanced as well as emerging market opportunities.
Aurobindo Pharma exports to over 125 countries across the globe with more than 70 per cent of its revenues derived out of international operations. The company makes use of in-house research and development (R&D) for rapid filing of patents, drug master files (DMFs), abbreviated new drug applications (ANDAs) and formulation dossiers across the world. It is among the largest filers of DMFs and ANDAs from India.
Aurobindo Pharma: Global Leadership in Anti-infectives
|2014||Completes the acquisition of select Western European Businesses of Actavis|
|2012||Launches its operations in the Kingdom of Bahrain|
|2011||Establishes joint venture with Diod (Russia) to manufacture and market generic drugs in Russia|
|2009||Receives two new registrations from Medicines Control Council (MCC), South Africa|
|2001||Set up first overseas manufacturing plant in China|